Abstract-We examined whether fingolimod (FTY720), an S1PR (sphingosine-1-phosphate receptor) modulator, has beneficial or harmful effects on mineralocorticoid/salt-induced renal injury. Uninephrectomized rats on 0.9% NaCl/0.3% KCl drinking solution were randomly divided into control, control+FTY720, deoxycorticosterone acetate (DOCA), and DOCA+FTY720 groups and administered vehicle, vehicle+FTY720, DOCA+vehicle, and DOCA+FTY720 for 4 weeks, respectively. Only the DOCA+FTY720 group had reduced survival rates and showed hemolysis because of intravascular mechanical fragmentation of erythrocytes and thrombocytopenia. Both the DOCA+FTY720 and DOCA groups developed malignant hypertension, which was more severe in the DOCA+FTY720 group. In the DOCA+FTY720 group only, thrombotic microangiopathy involving severe renal arteriole endothelial cell injury was observed and was characterized by fibrinoid necrosis and onion-skin lesions in arterioles. There were fewer circulating endothelial progenitor cells in the DOCA+FTY720 group but more in the DOCA group compared with the control group. Expression levels of VEGF (vascular endothelial growth factor), S1PR1, and S1PR3 in renal arteriole endothelial cells were significantly greater in the DOCA+FTY720 and DOCA groups compared with the control group, with levels being similar between the 2 groups. Expression levels of endothelial nitric oxide synthase in renal arteriole endothelial cells were significantly lower in the DOCA+FTY720 group only. The control+FTY720 group showed reduced circulating endothelial progenitor cells but no significant functional or pathological changes in kidneys or changes in blood pressure. Exposure of uninephrectomized rats to DOCA/salt+FTY720 for 4 weeks induced renal arteriolar endothelial cell injury, resulting in the development of thrombotic microangiopathy. Consideration of this possibility is recommended when prescribing FTY720. (Hypertension.
S 1P (sphingosine-1-phosphate), produced by phosphorylation of sphingosine by sphingosine kinases, is a biologically active lipid growth factor that binds to 5 cell-surface G protein-coupled high-affinity receptors (S1PR1-5) and regulates a spectrum of biological functions, including immune cell trafficking and functions, proliferation, cell survival, angiogenesis, endothelial cell (EC) barrier integrity, and extracellular matrix assembly.
1-3 S1PR1-3 are expressed in many cell types, including the kidneys, brain, liver, heart, and immune system, whereas S1PR4 and S1PR5 are mainly expressed in cells of the immune and nervous systems. [1] [2] [3] In the vasculature, S1PR1 and S1PR3 are mainly expressed in ECs. [1] [2] [3] Fingolimod (FTY720), an S1PR modulator, has recently been approved as the first oral treatment for relapsingremitting multiple sclerosis (MS) by the US Food and Drug Administration. [3] [4] [5] In vivo, FTY720 is phosphorylated by sphingosine kinases to form a potent S1P analog. The phosphorylated form binds to S1PR1 and S1PR3-5 and acts as an agonist or a functional antagonist, depending on the receptor subtype and the targeted cell type/tissue. [1] [2] [3] The main mode of action of FTY720 is to bind to S1PR1 on lymphocytes, to block lymphocyte egress from secondary lymphoid organs, and therefore to induce lymphopenia. FTY720 has been shown to exert renoprotection in many experimental kidney disease models, such as chronic anti-thy 1 glomerulosclerosis, 6 renal ischemia-reperfusion injury, 7, 8 subtotal nephrectomy, 9,10 hypertensive nephropathy, 11 antiglomerular basement membrane glomerulonephritis, 12 and cisplatin-induced acute kidney injury. 13 Nevertheless, adverse effects like hypertension have been reported after chronic treatment for MS patients. 14, 15 Furthermore, in cultured ECs, FTY720 impairs important endothelial functions by inhibiting S1P-mediated endothelial healing. 16 Excess mineralocorticoids from administration of aldosterone or deoxycorticosterone acetate (DOCA) together with salt induce malignant hypertension, which can result in damage to several organs, such as the kidneys and vasculature. [17] [18] [19] Kidney damage includes renal vascular injury, glomerulosclerosis, tubulointerstitial fibrosis, and renal inflammation. [17] [18] [19] However, it is unknown whether FTY720 has beneficial or harmful effects on mineralocorticoid/salt-induced renal injury. Therefore, we used uninephrectomized rats treated with DOCA and FTY720 together with salt for 4 weeks and observed functional and histological changes in the kidneys and changes in systolic blood pressure (SBP).
Methods
The authors declare that all supporting data are available within the article and in the online-only Data Supplement.
Animals
The study protocol was approved by the Jichi Medical University Animal Ethics Committee. Six-week-old male Sprague-Dawley rats (Clea Japan, Tokyo, Japan) weighing 180 to 220 g were housed in a temperature-controlled (23±2°C) and humidity-controlled (40% to 70%) room with a 12-hour light/dark cycle (lights on 07:00-19:00). The rats were anesthetized with an intraperitoneal injection of pentobarbital sodium (25 mg/kg, Kyoritsu Seiyaku, Tokyo, Japan), and the left kidney was removed. Immediately after nephrectomy, animals were randomly divided into 4 groups and administered either subcutaneous injection of DOCA (Sigma-Aldrich, St Louis, MO) at 20 mg per week and daily oral gavage of FTY720 (Novartis Pharma GmbH, Basel, Switzerland) for 4 weeks: control group (n=15), which received vehicle; DOCA group (n=15), which received DOCA plus vehicle; DOCA+FTY720 group, which received DOCA plus FTY720 at 0.5 or 1.0 mg/kg per day (FTY720 [0.5; n=10] or FTY720 [1.0; n=9], respectively); and control+FTY720(0.5) group (n=9), which received FTY720 at 0.5 mg/kg per day plus vehicle. All rats were then given 0.9% NaCl and 0.3% KCl as drinking water. Detailed Methods are available in the online-only Data Supplement.
Statistics
Results are presented as the mean±SEM. Data were analyzed using χ 2 tests, Student unpaired t tests, or ANOVA for repeated measures, followed by post hoc analysis with Fisher tests, where appropriate. A Kaplan-Meier curve was constructed to compare cumulative rat survival rates. Differences between groups were assessed using the log-rank test. A P value <0.05 was considered statistically significant.
Results
At week 4, the DOCA+FTY720(0.5) and DOCA+FTY720(1.0) groups showed significantly lower survival rates compared with the control and control+FTY720(0.5) groups, whereas the DOCA group showed similar survival rates to the control and control+FTY720(0.5) groups ( Figure 1A ). The DOCA+FTY720(1.0) group showed significantly lower survival rates than the DOCA group. Survival rates in the control and control+FTY720(0.5) groups were 100%. Because at week 4, the survival rates in the DOCA+FTY720(1.0) group were lower than those in the DOCA+FTY720(0.5) group, we failed to get enough blood from the DOCA+FTY720(1.0) group for measurement of blood hemoglobin levels and for blood platelet, lymphocyte, and neutrophil counts. We were also unable to record sufficient SBP values from the DOCA+FTY720(1.0) group. Accordingly, we analyzed data from the DOCA+FTY720(0.5) group only at week 4 for this purpose. At week 2, the 5 groups showed similar blood hemoglobin levels, whereas at week 4, the DOCA+FTY720(0.5) group alone showed significantly reduced hemoglobin levels compared with the other groups ( Figure 1B ). Hemoglobin levels from the only 2 rats of the DOCA+FTY720(1.0) group that survived for 4 weeks were 8.1 and 10.1 g/dL, both of which were lower than the levels in the DOCA+FTY720(0.5) group, and their peripheral blood smears showed numerous fragmented erythrocytes (schistocytes and helmet cells; Figure 1C ). At week 2, circulating platelet counts were similar among the 5 groups ( Figure 1D ). In the DOCA+FTY720(0.5) group at week 4, circulating platelet counts showed a tendency to decrease but did not reach statistical significance ( Figure 1D ). However, the number of rats with platelet counts <70×10 /µL, and these values were lower than those in the DOCA+FTY720(0.5) group. Taken together, the DOCA+FTY720(0.5) and DOCA+FTY720(1.0) groups at week 4 exhibited hemolysis because of intravascular mechanical fragmentation of erythrocytes and thrombocytopenia, with its extent being more severe in the DOCA+FTY720(1.0) group. At week 4, blood lymphocyte counts in the DOCA+FTY720(0.5) and control+FTY720(0.5) groups were significantly lower than those in the control and DOCA groups ( Figure S1A in the online-only Data Supplement), whereas neutrophil counts were similar among the groups ( Figure S1B ). FTY720 treatment selectively reduced blood lymphocyte counts in control and DOCA-treated rats.
At week 2, SBP was significantly higher in the DOCA, DOCA+FTY720(0.5), and DOCA+FTY720(1.0) groups compared with the control and control+FTY720(0.5) groups, with the magnitude in the DOCA+FTY720(1.0) group being significantly higher than that in the DOCA group but similar to that in the DOCA+FTY720(0.5) group ( Figure 1E ). SBP was further significantly elevated in the DOCA and DOCA+FTY720(0.5) groups at week 4 compared with that at week 2. At week 4, SBP was significantly higher in the DOCA and DOCA+FTY720(0.5) groups compared with the control and control+FTY720(0.5) groups, with the magnitude being significantly greater in the DOCA+FTY720(0.5) group ( Figure 1E) . SBP values from the only 2 rats of the DOCA+FTY720(1.0) group that survived for 4 weeks were 231 and 239 mm Hg, and these values were higher than those in the DOCA+FTY720(0.5) group. At week 2, glomerular function was similar among the groups because serum creatinine levels were not statistically different among them (control, 0. . However, at week 4, glomerular function was significantly reduced in the DOCA and DOCA+FTY720(0.5) groups because creatinine clearance was significantly lower in the DOCA and DOCA+FTY720(0.5) groups compared with the control and control+FTY720(0.5) groups, although it did tend to be lower in the DOCA+FTY720(0.5) group compared with the DOCA group but did not reach statistical significance ( Figure 1F ). At week 4, creatinine clearance values in the only 2 rats of the DOCA+FTY720(1.0) group that survived for 4 weeks were 0.40 and 0.45 mL/min per 100 g body weight, and these values were lower than those in the DOCA+FTY720(0.5) group. At week 4, values for urinary protein excretion and urinary N-acetyl-β-glucosaminidase in the DOCA and DOCA+FTY720(0.5) groups were significantly greater than those in the control and control+FTY720(0.5) groups, with the values being similar between the 2 groups ( Figure S1C and S1D). The above-mentioned 4 parameters in the control+FTY720(0.5) group were comparable with the control group (Figure 1E and 1F; Figure S1C and S1D).
The findings observed in the DOCA+FTY720(0.5) and DOCA+FTY720(1.0) groups alone at week 4 suggested the possible presence of renal thrombotic microangiopathy (TMA). To determine whether this was correct, we stained the control, control+FTY720(0.5), DOCA, and DOCA+FTY720(0.5) groups of rat kidneys at week 4 with Masson's trichrome, ECs with anti-rat EC antibody-1, and picrosirius red. Histological examination of the DOCA+FTY720(0.5) group showed vascular, glomerular, and tubulointerstitial lesions with severe involvement of the arterioles (Figure 2 ; Figures S2 and S3 ). In the DOCA+FTY720(0.5) group, vascular thrombotic lesions (VTLs) were observed in most arterioles and were characterized by the appearance of fibrinoid necrosis ( Figure 2A ). The number of fibrinoid necrotic lesions was significantly greater in the DOCA+FTY720(0.5) group compared with the other groups ( Figure 2A ). Marked EC injuries were suggested by the partially blurred and decreased immunogenicity for anti-rat EC antibody-1 ( Figure 2B ). In fact, the numbers of arteriole ECs with decreased immunogenicity for anti-rat EC antibody-1 were significantly higher in the DOCA+FTY720(0.5) and DOCA groups compared with those in the control and control+FTY720(0.5) groups, with the magnitude being significantly greater in the DOCA+FTY720(0.5) group ( Figure 2B ). Some arteriole lumens showed fragmented erythrocytes characteristic of TMA (Figure 2A , black arrows). Arteriole EC injuries were also characterized by denuded or swollen ECs surrounded by mucinous extracellular matrix and nodular thickening, consistent with obliterative proliferative arteriolopathy ( Figure 2C ). The number of VTLs was significantly greater in the DOCA+FTY720(0.5) group compared with the other groups ( Figure 2C ). In this group, glomerular thrombotic lesions, characterized by fibrin thrombi accompanied by swelling and edematous expansion of mesangial areas without significant hypercellularity, were also observed in some glomerular capillary loops and extended from the VTLs in arterioles ( Figure 2B and 2C) . The number of glomerular thrombotic lesions was also significantly greater in the DOCA+FTY720(0.5) group compared with the other groups ( Figure 2C ). By contrast, in the DOCA group, both VTLs and glomerular thrombotic lesions were rarely observed; however, their numbers tended to increase compared with the control and control+FTY720(0.5) groups but did not reach statistical significance. Furthermore, in the control+FTY720(0.5) Figure 1 . Effect of fingolimod (FTY720) on survival rate, blood hemoglobin levels, peripheral blood smears, blood platelet counts, systolic blood pressure (SBP), and creatinine clearance (CCr). A, Survival rates from the beginning of treatment in the studied rat groups. Uninephrectomized rats were divided into following: control group (n=15), which received vehicle; deoxycorticosterone acetate (DOCA) group (n=15), which received DOCA plus vehicle; DOCA+FTY720 group, which received DOCA plus FTY720 at 0.5 or 1.0 mg/kg per day (FTY720 [0.5; n=10] or FTY720 [1.0; n=9], respectively); and control+FTY720(0.5) group, which received vehicle plus FTY720 at 0.5 mg/kg per day. B, Blood hemoglobin levels in the 4 and 5 groups of rats at weeks 2 and 4, respectively. Control, control+FTY720(0.5), DOCA, DOCA+FTY720(0.5), DOCA+FTY720(1.0). Values are mean±SEM of 5 to 6 rats/ group and 6 to 9 rats/group at weeks 2 and 4, respectively. *P<0.05 vs control; +P<0.05 vs DOCA; •P<0.05 vs control+FTY720(0.5). C, Representative micrograph of fragmented erythrocytes (schistocytes and helmet cells) from a peripheral blood smear from the DOCA+FTY720(1.0) group at week 4 (magnification ×400). D, Blood platelet counts in the 4 and 5 groups of rats at weeks 2 and 4, respectively. Control, control+FTY720(0.5), DOCA, DOCA+FTY720(0.5), DOCA+FTY720(1.0). Values are mean±SEM of 5 to 6 rats/group and 6 to 9 rats/group at weeks 2 and 4, respectively. E, SBP in the 4 or 5 groups of rats at weeks 0, 2, and 4. Control, control+FTY720(0.5), DOCA, DOCA+FTY720(0. group, neither the numbers of VTLs nor glomerular thrombotic lesions differed from the control group.
The glomerular collagen volume fraction was significantly greater in the DOCA and DOCA+FTY720(0.5) groups compared with the control and control+FTY720(0.5) groups, being greatest in the DOCA+FTY720(0.5) group ( Figure  S2A ). Of note, however, in the DOCA+FTY720(0.5) group at week 4, most glomeruli had collapsed, consistent with ischemia characterized by wrinkling of capillary loops and collapse of capillary lumina ( Figure 2C) ; therefore, the glomerular area was significantly smaller than that in the other groups ( Figure 2C ). This meant that the glomerular collagen volume fraction corrected to glomerular area was similar between the DOCA and DOCA+FTY720(0.5) groups ( Figure S2B ). Accordingly, in this group, glomerular lesions were probably secondary to preglomerular vascular occlusion caused by VTLs. In the DOCA group, the glomerular area was significantly greater than in the control group ( Figure 2C) . The tubulointerstitial collagen volume fraction was significantly greater in the DOCA and DOCA+FTY720(0.5) groups compared with the control and control+FTY720(0.5) groups and was similar between the 2 ( Figure S2C ). Both glomerular capillary and peritubular capillary densities were significantly lower in the DOCA and DOCA+FTY720(0.5) groups compared with the control and control+FTY720(0.5) groups, with densities being similar between the 2 former groups ( Figure  S3 ). In the control+FTY720(0.5) group, the above histological parameters were all comparable with those in the control group ( Figure 2C ; Figure S2-S3) . These results are consistent with the notion that the DOCA+FTY720(0.5) group at week 4 alone exhibited significant renal arteriole EC injuries and consequently TMA. These histological findings in the renal arterioles of the 4 groups correlated with serum Ang II (angiotensin II) levels, which were significantly greater in the DOCA+FTY720(0.5) group but significantly lower in the DOCA group ( Figure S4 ).
Because bone marrow-derived endothelial progenitor cells (EPCs) can be recruited to the site of injury to replace injured ECs and contribute to their repair, 20 we next examined the number of circulating EPCs in the 4 groups of rats at week 4. The numbers of EPCs were significantly lower in the control+FTY720(0.5) and DOCA+FTY720(0.5) groups but significantly greater in the DOCA group compared with the control group (Figure 3) . In a rat model of TMA caused by glomerular EC injuries 21 and in a murine model of TMA induced by glomerular and peritubular EC injuries, 22 levels of VEGF (vascular endothelial growth factor) were increased in the kidneys. Both VEGF and S1P independently and synergistically stimulate angiogenesis. [23] [24] [25] Furthermore, crosstalk between VEGF and S1PR1 in vascular ECs has been reported. 26 Therefore, we examined the expression levels of VEGF, S1PR1, and S1PR3 in renal arteriole ECs from the 4 groups of rat kidneys at week 4 using immunohistochemistry. Expression levels of VEGF, S1PR1, and S1PR3 in arteriole ECs were all significantly elevated in the DOCA+FTY720(0.5) and DOCA groups compared with the control and control+FTY720(0.5) groups, being similar between the 2 groups, although they were not significantly different between the control and control+FTY720(0.5) groups (Figure 4) .
Cantalupo et al 27 have recently shown that chronic treatment of mice with FTY720 induced a marked reduction of S1PR1 protein expression in mesenteric artery endothelial, thereby inhibiting the S1PR1-dependent eNOS (endothelial nitric oxide synthase)-nitric oxide (NO) activation pathway, resulting in increased SBP in control mice and exacerbated hypertension in Ang II model mice. We, therefore, examined the expression levels of eNOS in renal arteriole ECs from kidneys of the 4 groups at week 4 using immunohistochemistry. Expression levels of eNOS in arteriole ECs were significantly reduced in the DOCA+FTY720(0.5) group only ( Figure 5 ).
To examine whether lymphocyte infiltration into the injured kidney tissues is involved in the arteriole EC injuries observed in the DOCA+FTY720(0.5) group at week 4, we immunohistochemically stained T lymphocytes with an anti-CD3 antibody and B lymphocytes with an anti-CD20 antibody in kidney sections of the 4 groups at week 4. There were few CD3-positive T lymphocytes and CD20-positive B lymphocytes in periarteriolar areas in all 4 groups, but their expression levels were similar among the 4 groups; however, many CD3-positive T lymphocytes and CD20-positive B lymphocytes were observed in the spleen of the control rats ( Figure  S5 ). Accordingly, the arteriole EC injuries observed in the DOCA+FTY720(0.5) kidneys at week 4 must have occurred independently of lymphocyte infiltration into the injured kidney tissues.
Discussion
In this study, we found that at week 4, the DOCA+FTY720 group alone dose-dependently exhibited TMA, with the most severe renal arteriole EC injuries occurring independently of lymphocyte infiltration into the injured kidney tissues, resulting in reduced survival rates, although at week 2 the DOCA+FTY720 group did not exhibit TMA. This finding markedly contrasts with studies describing the renoprotective effects of FTY720 in many experimental kidney disease models. [6] [7] [8] [9] [10] [11] [12] [13] Some of these studies postulated the main mechanism for this renoprotection to be a block of lymphocyte egress from lymphoid tissues 28 and a subsequent inhibition of lymphocyte infiltration into injured kidney tissues. 6, [9] [10] [11] Because endothelial injury is the principal mechanism underlying TMA, the renal TMA observed in the DOCA+FTY720 group at week 4 was thought to be caused by renal arteriole EC injuries and associated with chronic treatment with FTY720. This suggestion is supported by a study that used cultured ECs and reported that FTY720 impairs important endothelial functions by inhibiting S1P-mediated endothelial healing. 16 At week 2, SBP elevation was greater in the DOCA+FTY720(1.0) group than in the DOCA group. At Figure 4 . Effect of fingolimod (FTY720) on the protein levels of VEGF (vascular endothelial growth factor), S1PR (sphingosine-1 phosphate receptor) 1 and S1PR3 in renal arteriole endothelial cells (ECs). Representative micrographs of immunostaining for VEGF (A), S1PR1 (B), and S1PR3 (C) in kidneys of the 4 groups at week 4. White arrows show renal arterioles. Representative negative control micrograph without primary antibody of a deoxycorticosterone acetate (DOCA) group kidney at week 4 (D). Scale bars: 50 μm. E, Comparison of grading scores for protein expression levels of VEGF, S1PR1, and S1PR3 among the 4 groups of rat kidney arteriole endothelial cells at week 4. Control, control+FTY720(0.5), DOCA, DOCA+FTY720(0.5). Results are mean±SEM of 4 to 5 rats/group. *P<0.05 vs control; •P<0.05 vs control+FTY720(0.5). week 4, SBP elevation was also more prominent in the DOCA+FTY720(0.5) group than in the DOCA group. It is possible that severe hypertension induced by chronic treatment with FTY720 may have induced renal arteriole EC injuries, leading to the development of TMA. In phase II and III clinical trials, a modest rise in BP (3-5 mm Hg) was observed in MS patients chronically receiving FTY720. 14, 15 In rats, the daily oral administration of FTY720 for 10 days significantly raised mean BP in a dose-dependent manner, 29 whereas a single dose of FTY720 further increased mean arterial BP in spontaneously hypertensive rats after 24 hours. 30 In mice, chronic treatment of FTY720 elevated SBP in control mice and exacerbated hypertension in Ang II model mice. 27 However, the underlying mechanisms remained unclear.
Animals with DOCA/salt hypertension develop malignant hypertension, despite low levels of plasma renin activity. 17 In the DOCA+FTY720 group at week 4, renal arteriole microvascular thrombosis reduced glomerular perfusion, resulting in the activation of the renin-angiotensin-aldosterone system. This process worsens malignant hypertension and contributes to the pathogenesis of renal TMA. This notion is also supported by the fact that at week 4, serum Ang II levels were significantly higher in the DOCA+FTY720(0.5) group and were significantly lower in the DOCA group compared with those in the other groups ( Figure S4 ). An alternative mechanism for the severe hypertension observed in the DOCA+FTY720 group at week 4 is the downregulation of eNOS in renal arteriole ECs ( Figure 5 ). This possibility is supported by a recent report by Cantalupo et al, 27 in which chronic treatment of mice with FTY720, acting as a functional S1PR1 antagonist, induced S1PR1 downregulation in resistance arteries and consequent inhibition of S1PR1-dependent eNOS-NO pathway activation, leading to BP elevation.
We also found that at week 4, the DOCA+FTY720(0.5) group exhibited significantly reduced circulating EPCs compared with the control group. Circulating EPCs increase during the acute phase of autoimmune thrombotic thrombocytopenic purpura, one of the major types of TMA, and return to baseline levels during remission. 31 After EC injury, bone marrowderived EPCs can be recruited to the site of injury to replace injured ECs and contribute to their repair. 20 In a murine model of TMA, glomerular and peritubular capillary EC injuries were reported to result in marked stimulation of EPCs and various angiogenic factors, such as VEGF, orchestrating microvascular repair. 32 Therefore, the renal arteriole EC injuries observed in the DOCA+FTY720(0.5) group at week 4 may have been caused by inhibition of EC repair via reduced circulating EPCs induced by chronic treatment with FTY720. This suggestion is supported by a study by Li et al, 33 in which chronic FTY720 treatment reduced circulating EPCs and consequently suppressed liver tumor metastasis after a major hepatectomy and ischemia-reperfusion injury together with less tumor angiogenesis. However, a direct effect of FTY720 on the generation of EPCs in bone marrow cannot be excluded.
VEGF is induced in response to hypoxia and is the major proangiogenic cytokine. In animal models of renal TMA, expression of VEGF is upregulated in the kidneys and is important for EC regeneration after injury. 21, 22 As mentioned above, chronic treatment of mice with FTY720 induced marked downregulation of S1PR1 protein expression and consequent inhibition of S1PR1-dependent eNOS-NO pathway activation in mesenteric artery endothelial. 27 In the current study, however, expression levels of VEGF, S1PR1, and S1PR3 in arteriole ECs were all significantly greater in the DOCA+FTY720(0.5) and DOCA groups compared with the control group, with levels being comparable between the 2 groups. Nevertheless, severe EC injuries and the resultant renal TMA were only observed in the DOCA+FTY720(0.5) group. It is unknown why upregulation of VEGF, S1PR1, and S1PR3 did not contribute to EC repair in this group. We also observed eNOS downregulation in renal arteriole ECs in this group only ( Figure 5 ). Murohara et al 25 reported that eNOS acts as a downstream signal of VEGF and induced angiogenesis in response to tissue ischemia in vivo. Therefore, a possible explanation is that under the condition of eNOS downregulation, expression levels of VEGF, S1PR1, and S1PR3 in injured ECs in this group are insufficient for regeneration and for angiogenesis after arteriole EC injury. These suggestions require further study. Taken together, circulating EPC-VEGF-S1PR1-S1PR3-eNOS-NO signaling may mutually interact and be involved in the pathogenesis of the renal TMA observed in the DOCA+FTY720 group at week 4. These possibilities need further investigation.
Another finding of this study was that the DOCA group at week 4 exhibited malignant hypertension with arteriole EC injuries but not renal TMA. The absence of TMA did not influence survival rates, although at week 4, values for creatinine clearance, urinary protein excretion, urinary N-acetyl-β-glucosaminidase, corrected glomerular collagen volume fraction, tubulointerstitial collagen volume fraction, and densities of glomerular and peritubular capillaries in the DOCA group were comparable with those in the DOCA+FTY720(0.5) group. Furthermore, arteriole EC injuries were observed in the DOCA group but were milder than those in the DOCA+FTY720(0.5) group. It should be noted that at week 4, the number of circulating EPCs in the DOCA group was significantly greater than that in the control and DOCA+FTY720(0.5) groups, and expression of VEGF, S1PR1, and S1PR3 in arteriole ECs was also significantly greater than the control group. Therefore, elevated levels of circulating EPCs may have resulted in effective EC regeneration via upregulation of VEGF, S1PR1, and S1PR3, resulting in a lack of significant renal TMA.
The final finding of this study was that the control+FTY720(0.5) group at week 4 exhibited reduced circulating lymphocytes and EPCs, but this had no effect on survival rates, levels of blood hemoglobin and platelets, SBP, or functional or histological parameters in the kidneys. Similarly, Tawadrous et al 34 reported that oral treatment of rats with FTY720 at therapeutic doses (0.3-1.0 mg/ kg per day) for 7 days showed no significant pathological alterations or functional changes in the kidneys, or on BP, although they did not measure circulating lymphocytes or EPCs. Therefore, severe hypertension, as well as functional and morphological alterations observed in the kidneys of the DOCA+FTY720 group at week 4 is specific to rats treated with DOCA+FTY720 for 4 weeks.
Perspectives
Treatment of uninephrectomized rats with DOCA/salt+FTY720 for 4 weeks induced renal arteriole EC injuries, resulting in the development of TMA. The possible underlying mechanisms involve exacerbated malignant hypertension, reduced circulating EPCs, and insufficient expression levels of VEGF, S1PR1, and S1PR3 and reduced expression levels of eNOS in the injured ECs, all of which were induced by chronic treatment with FTY720. These possibilities need future investigation. TMA associated with severe or malignant hypertension has been reported in 4 patients with MS who were receiving therapy with recombinant interferon-β. 35 Furthermore, anti-VEGF agents, such as bevacizumab, the humanized monoclonal antibody for VEGF, 36 have been shown to cause hypertension and TMA. When prescribing these drugs for MS patients who are taking FTY720 chronically, neurologists should be aware of this potential association, as early recognition and prompt therapeutic intervention might prove beneficial.
